{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:28:06Z","timestamp":1790605686324,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Adverse drug reactions (ADRs) have posed significant threats to patient safety and could potentially result in adverse clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we analyzed ADRs data reported by a large hospital spanning from 2020 to 2023, with a particular focus on identifying demographic and clinical factors associated with severe ADRs. The dataset encompassed 5,644 cases, incorporating variables such as patient age, gender, smoking and drinking history, allergies, medication type, and administration route.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among these, 408 cases of severe ADRs underwent detailed examination. Additionally, the study delved into the correlation between adverse drug reactions symptoms (ADRS) and various drug types. According to research statistics, individuals in the middle-aged group (46\u201365 years) exhibited the highest proportion of severe ADRs at 36.77%. Females were significantly more affected than males, accounting for 66.67% of severe ADRs. Anti-tumor drugs emerged as the primary cause of severe ADRs, responsible for 52.70% of such incidents. Compared with other administration methods, intravenous injection was more prone to causing severe ADRs, with a likelihood of 53.92%. Furthermore, the blood system was identified as the ADRS where severe ADRs occurred at a significantly higher rate than other parts of the body, at 53.19%. Correlation analysis reveals a strong association between medication type and factors such as patient age, administration route, and ADRS. Notably, ADRS was also strongly linked to drug type, gender, and age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings collectively highlight the critical need for personalized treatment plans and targeted monitoring. Particular attention should be directed towards high-risk groups, such as middle-aged females and patients undergoing anti-tumor therapies. By doing so, it is possible to enhance drug safety and minimize the occurrence of severe ADRs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1628347","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:34:57Z","timestamp":1759383297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A comprehensive analysis of adverse drug reactions in 2020\u20132023: case studies"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinghui","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhe","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/bcp.12944","article-title":"Adverse drug event reporting systems: a systematic review","volume":"82","author":"Bailey","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"107223","DOI":"10.1016\/j.vph.2023.107223","article-title":"Antineoplastic drugs inducing cardiac and vascular toxicity - an update","volume":"153","author":"Barachini","year":"2023","journal-title":"Vasc. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","article-title":"Epidemiology of adverse drug reactions in Europe: a review of recent observational studies","volume":"38","author":"Bouvy","year":"2015","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.2021.13844","article-title":"US emergency department visits attributed to medication harms, 2017-2019","volume":"326","author":"Budnitz","year":"2021","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"13302","DOI":"10.3390\/ijms222413302","article-title":"Genophenotypic factors and pharmacogenomics in adverse drug reactions","volume":"22","author":"Cacabelos","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF03319099","article-title":"A review of pharmacogenetics of adverse drug reactions in elderly people","volume":"35","author":"Cardelli","year":"2012","journal-title":"Drug Saf."},{"key":"B7","first-page":"456","article-title":"Biostatistics 301A. Repeated measurement analysis (mixed models)","volume":"45","author":"Chan","year":"","journal-title":"Singap. Med. J."},{"key":"B8","first-page":"354","article-title":"Biostatistics 301. Repeated measurement analysis","volume":"45","author":"Chan","year":"","journal-title":"Singap. Med. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"Cd008398","DOI":"10.1002\/14651858.CD008398.pub2","article-title":"Oral versus intravenous fluoropyrimidines for colorectal cancer","volume":"7","author":"Chionh","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"B12","doi-asserted-by":"publisher","first-page":"104122","DOI":"10.1016\/j.etap.2023.104122","article-title":"Antineoplastic drugs in environmentally relevant concentrations cause endocrine disruption and testicular dysfunction in experimental conditions","volume":"100","author":"da Cunha de Medeiros","year":"2023","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/IPRP.S108047","article-title":"Role of the pharmacist in reducing healthcare costs: current insights","volume":"6","author":"Dalton","year":"2017","journal-title":"Integr. Pharm. Res. Pract."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/bcp.13923","article-title":"Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in The Netherlands: an explorative observational study","volume":"85","author":"de Vries","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1124\/pr.111.004614","article-title":"Organic anion transporters and their implications in pharmacotherapy","volume":"64","author":"Emami Riedmaier","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14740338.2018.1491547","article-title":"The economic burden of preventable adverse drug reactions: a systematic review of observational studies","volume":"17","author":"Formica","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","article-title":"Ibrutinib dose modifications in the management of CLL","volume":"13","author":"Hardy-Abeloos","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.annemergmed.2011.01.003","article-title":"Outcomes of emergency department patients presenting with adverse drug events","volume":"58","author":"Hohl","year":"2011","journal-title":"Ann. Emerg. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.drudis.2019.03.003","article-title":"Machine learning on adverse drug reactions for pharmacovigilance","volume":"24","author":"Lee","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1517\/17425255.2012.665874","article-title":"Predicting and detecting adverse drug reactions in old age: challenges and opportunities","volume":"8","author":"Mangoni","year":"2012","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1111\/jan.14565","article-title":"Peripheral intravenous catheter non-infectious complications in adults: a systematic review and meta-analysis","volume":"76","author":"Marsh","year":"2020","journal-title":"J. Adv. Nurs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.11613\/bm.2013.018","article-title":"The chi-square test of independence","volume":"23","author":"McHugh","year":"2013","journal-title":"Biochem. Med. Zagreb."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e00541","DOI":"10.1002\/prp2.541","article-title":"Individualized medicine: sex, hormones, genetics, and adverse drug reactions","volume":"7","author":"Moyer","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"B27","volume-title":"International drug monitoring: the role of national centres, report of a WHO meeting [held in Geneva from 20 to 25 September 1971]","author":"Organization","year":"1972"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.thromres.2021.12.017","article-title":"Cardiovascular toxic effects of antitumor agents: pathogenetic mechanisms","volume":"213","author":"Pantazi","year":"2022","journal-title":"Thromb. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S1470-2045(16)30312-6","article-title":"21st century pharmacovigilance: efforts, roles, and responsibilities","volume":"17","author":"Pitts","year":"2016","journal-title":"Lancet Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-021-00474-4","article-title":"Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer","volume":"18","author":"Ragoonanan","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.annemergmed.2009.10.012","article-title":"Medication errors recovered by emergency department pharmacists","volume":"55","author":"Rothschild","year":"2010","journal-title":"Ann. Emerg. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1517\/17425255.4.4.413","article-title":"Sex-specific differences in CYP450 isoforms in humans","volume":"4","author":"Scandlyn","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/978-3-642-30726-3_19","article-title":"Sex differences in the drug therapy for oncologic diseases","author":"Schmetzer","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1213\/ANE.0000000000004410","article-title":"Chi-square tests in medical research","volume":"129","author":"Schober","year":"2019","journal-title":"Anesth. and Analgesia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bcp.15277","article-title":"Pharmacovigilance in China: evolution and future challenges","volume":"89","author":"Song","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/03602530903401658","article-title":"Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective","volume":"42","author":"Tang","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's oncology group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijpharm.2013.08.079","article-title":"Nanocarriers for intravenous injection--the long hard road to the market","volume":"457","author":"Wacker","year":"2013","journal-title":"Int. J. Pharm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.numecd.2020.07.032","article-title":"Epidemiology of dyslipidemia and associated cardiovascular risk factors in northeast China: a cross-sectional study","volume":"30","author":"Xing","year":"2020","journal-title":"Nutr. Metab. Cardiovasc Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12603-020-1311-x","article-title":"A multicenter study of multimorbidity in older adult inpatients in China","volume":"24","author":"Zhang","year":"2020","journal-title":"J. Nutr. Health Aging"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1628347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:34:58Z","timestamp":1759383298000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1628347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":37,"alternative-id":["10.3389\/fphar.2025.1628347"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1628347","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1628347"}}